Werewolf Therapeutics, Inc.
HOWL Nasdaq
SEC CIK 1785530
Follow Werewolf Therapeutics
Weekly email: filings, results
Net income
−$9.9M
+39.7% vs same quarter last year
EPS, diluted
−$0.20
+44.4% vs same quarter last year
Operating cash flow
−$9M
+40.8% vs same quarter last year
Operating income
−$10.1M
+36.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$60.8M |
| FY24 | −$70.5M |
| FY23 | −$37.4M |
| FY22 | −$53.8M |
| FY21 | −$50M |
| FY20 | −$15M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$60.3M |
| FY24 | −$56.4M |
| FY23 | −$33.4M |
| FY22 | −$44.2M |
| FY21 | −$43.4M |
| FY20 | −$19.2M |
| FY19 | - |